Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zorpreva is a collagen-based, biodegradable, fully bioresorbable pharmaceutical or medical-device product developed using Innocoll’s proprietary collagen technology platform. It is one of a family of type I collagen matrices manufactured by Innocoll for local application at wound or surgical sites, designed to deliver therapeutic benefit directly to the target tissue while minimizing systemic exposure. Although Zorpreva is listed by Innocoll as an approved collagen product sold via strategic partnerships, publicly available sources do not specify its exact active pharmaceutical ingredient, indication, or detailed mechanism of action, beyond its characterization as a collagen-based, locally applied product in the company’s collagen implant portfolio.[6][12][14][16]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zorpreva.